- Home
- SCYX
SCYX
SCYNEXIS Inc.
as 11-21-2024 3:40pm EST
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 50.3M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 165.3K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $3.07 | Next Earning Date: | 11-06-2024 |
| Revenue: | $8,566,000 | Revenue Growth: | -93.70% |
| Revenue Growth (this year): | -87.02% | Revenue Growth (next year): | 145.59% |
Stock Insider Trading Activity of SCYNEXIS Inc. (SCYX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Angulo Gonzalez David | SCYX | Chief Executive Officer | Sep 12 '24 | Buy | $1.37 | 20,000 | $27,400.00 | 507,871 |
Latest SCYNEXIS Inc. News
SCYX Breaking Stock News: Dive into SCYX Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Associated Press Finance
15 days ago
Scynexis: Q3 Earnings Snapshot
GlobeNewswire
16 days ago
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Simply Wall St.
23 days ago
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years
GlobeNewswire
a month ago
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
GuruFocus.com
a month ago
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc
GlobeNewswire
2 months ago
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
GlobeNewswire
3 months ago
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
Compare SCYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCYX SCYNEXIS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.